Beam Therapeutics Inc (BEAM) Stock Price & News

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia

About Beam Therapeutics Inc

CEOJohn Evans

Employees540

Founded2017

Headquarters-

Sector-

Websitebeamtx.com

All values in USD	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	9,70 m	114,11 m	31,74 m	490,00 k
Cost of goods sold	109,77 m	99,28 m	104,52 m	95,10 m
Cost of revenue	109,77 m	99,28 m	104,52 m	95,10 m
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	26,74 m	32,28 m	34,43 m	31,95 m
Operating expense	26,74 m	32,28 m	34,43 m	31,95 m
Total operating expenses	136,51 m	131,55 m	138,95 m	127,04 m
Operating income	-126,81 m	-17,44 m	-107,22 m	-126,55 m
Other non operating income	8,55 m	50,00 k	2,50 m	-4,20 m
EBT including unusual items	-112,73 m	244,30 m	-94,32 m	-122,68 m
EBT excluding unusual items	-118,26 m	248,39 m	-94,85 m	-123,27 m
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-112,73 m	244,30 m	-94,32 m	-122,68 m
Net profit margin	-1 162,38%	214,09%	-297,18%	-25 036,33%
Earnings per share	-1,10	2,33	-0,91	-1,18
Interest and investment income	-	10,64 m	9,87 m	7,49 m
Interest expense	-	-	-	-
Net interest expenses	-	10,64 m	9,87 m	7,49 m
Depreciation and amortization charges	-	-	-	-
EBITDA	-121,25 m	-11,78 m	-101,61 m	-121,14 m
Gain or loss from assets sale	-	-	-	44,00 k

Ask anything